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Methods of anatomical and metabolic imaging 
in head and neck region tumors
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The incidence of head and neck cancer (HNC) ranges from 5.5% to 6.2% of general cancer incidence in Poland as well 
as in other European countries and in the US. Precise evaluation of the clinical stage in this group of patients allows for 
personalized treatment, inter alia, to choose proper surgery technique, to plan and verify radiation therapy. It is a result 
of availability of wide spectrum of imaging methods currently used in oncology. These methods are also used in the 
suitable assessment of antineoplastic therapy effects, which gives the chance of early detection of cancer progression.
Methods of imaging diagnostics — anatomical and metabolic — differ in terms of sensitivity, specificity and diagnostic 
accuracy. Each of them has advantages and disadvantages in imaging of HNC, hence, choice of treatment method 
should not be made based on single imaging modality. Increasingly, information obtained from alternative imaging 
studies support optimal decision in everyday clinical practice.
This review describes clinical usefulness of currently available morphological and metabolic imaging methods in 
HNC patients, with particular emphasis on innovative technologies, like PET/MR hybrid.
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Introduction
Head and neck cancers (HNC) are a significant clinical 
and social problem. In Poland, the incidence of HNC (except 
for thyroid cancer) in recent years ranges from 5.5% to 6.2% 
of the total number of cases of malignant tumors. Similar 
incidence rates also apply to other European countries and 
the United States [1]. Accurate assessment of the clinical 
stage in this group of patients is essential to select the 
best treatment strategy. The challenge is not only to define 
precisely the T and N parameters (according to TNM clas-
sification), but also to detect possible metastatic lesions 
and identify the primary lesion in patients with initially 
diagnosed lymph node metastases [2]. Currently we have a 
variety of head and neck imaging methods available, such 
as ultrasonography (USG), X-ray, computed tomography 
(CT), magnetic resonance imaging (MRI), positron emission 
tomography (PET) using various radiotracers — integrated 
with CT or MRI. Dynamic technological development of 
these methods has been observed for years. Each of them 
has its own strengths and weaknesses in imaging diagno-
stics, but the right choice of these examinations allows to 
find answers to clinical questions about the location and 
grade of the cancer. Increasingly common information obta-
ined thanks to them supports making the right therapeutic 
decision, precise implementation of medical procedures 
(e.g. scope of surgeries, radiotherapy) and monitoring of 
treatment results.
Ultrasonography 
Ultrasound examination is a commonly used technique 
in clinical practice. This method is best suited for the dia-
gnosis of cervical lymph nodes [2, 3]. The sensitivity of this 
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examination oscillates around 94%, its specificity — 77% 
[4–7]. Ultrasound can detect pathologies such as necrosis 
or microcalcifications in lymph nodes of normal size. It is 
possible to distinguish inflammatory lymphadenopathy 
from metastatic lymph nodes, e.g. by finding differences 
in vascularity and blood flow observed with color Doppler 
ultrasound [3, 8]. The size of the lymph node, its shape, 
echogenicity, structure and image of the hilum are asses-
sed on a gray scale. An enlarged (> 10 mm), reactive lymph 
node is usually oval in shape, its echogenicity is reduced, 
structure is uniform and hilum is clearly marked. A neo-
plastic lymph node is round-shaped, with heterogeneous 
structure, invisible nodal hilum and decreased echogeni-
city [3]. Lymph nodes are evaluated and measured in real 
time, which accelerates the diagnosis and introduction of 
possible treatment [9]. An additional option of ultrasound 
imaging, i.e. elastography, allows to show the cohesiveness 
of the evaluated tissues with a color scale — lesions with a 
greater cohesiveness may suggest a neoplastic background. 
Modern ultrasound devices provide high quality images, 
making this examination one of the basic tools for soft tis-
sues and superficial organs imaging [3]. On the other hand, 
lymph nodes of some groups lying deeper are beyond the 
scope of the examination, e.g. retropharyngeal lymph nodes 
(group VII), which may be the location of metastases from 
the nasal and the oral pharynx [8]. 
Ultrasound examination can also be used in the evalu-
ation of tumor (T parameter according to TNM) in oral ca-
vity cancers, most often tongue cancers. For this purpose, 
a suitable intraoral ultrasonography (IOUS) probe is used, 
which allows to assess the thickness of the infiltration and 
the structure of cancer tissue [10]. Ultrasonography is also a 
commonly used method in the diagnosis of secondary focal 
abnormalities in the liver, which is the third most frequent lo-
calization of HNC distant metastases [11, 12]. The sensitivity of 
liver metastatic lesions detection can be increased by 30–40% 
due to the administration of ultrasound contrast agents. They 
consist of microbubbles of air suspended in human albumin 
or galactose solution, and their presence in the vessels of the 
examined tissue amplifies the signal returning to the receiver 
in the probe [13]. The advantage of ultrasound techniques 
over other imaging methods is low examination costs and 
wide access to ultrasound devices. Ultrasonography is often 
used in post-treatment follow-up of HNC patients, especially 
in follow-up examinations of the regional lymphatic system 
[14]. Sensitivity and specificity of ultrasound examinations 
in diagnostics of local and regional recurrence is high and 
amounts to 81% and 87%, respectively [15]. In addition, ul-
trasound plays a key role during imaging-guided biopsy, 
as it enables the selection of the optimal place from which 
the material will be collected, allowing for histopathological 
verification of the lymph node or superficially located tumor 
detected by examination [2]. However, the basic limitation of 
this method is that the precision of the study result depends 
on the experience and manual skills of the doctor performing 
the examination [8].
Ultrasound evaluation is also used in IGRT (image-gu-
ided radiation therapy), where it is adapted to verify the posi-
tion of the patient with highly specialized RT techniques [16, 
17]. Ultrasound allows to monitor changes in the structure 
of salivary glands under the influence of X-rays during RT 
in HNC, which in the future may result in better protection 
of the salivary glands and prevention of xerostomia [18]. 
X-ray
X-rays are the most available and cheapest imaging me-
thod [19]. Currently, the number of indications for the use of 
X-ray examination in HNC diagnostics has decreased due to 
the development of such imaging techniques, as CT or MR.
An X-ray examination in the form of a dental panoramic 
radiograph makes it possible to visualize the neoplastic infil-
tration in the mandible or bone structures of the ethmoido-
-maxillary massif in the case of advanced cancers of these 
regions [20, 21]. In addition, a dental panoramic radiograph 
performed before the start of radiation therapy (RT) in the 
head and neck region also serves to assess the condition of 
the dentition and to identify possible odontogenic foci, thus 
supporting a dentist’s decisions during oral cavity sanitation 
before RT [22, 23].
On the other hand, X-ray examination in Waters view 
(an occipitomental view) is a baseline study in diagnostics 
of facial pathology. An X-ray taken in this way is a summary 
projection of the head structures, which makes it possible 
to assess only large sinuses: frontal and maxillary, namely: 
the level of fluid in the sinuses, significant thickening of the 
mucous membranes, the location of polyps and abnormal 
aeration of the sinuses [16, 24].
In X-ray examinations, a characteristic phenomenon is 
the formation of high contrast between bone tissue and sur-
rounding soft tissues, which is related to the different chemi-
cal structure of these tissues and the physical interaction of 
X-rays with the matter. The lack of these differences between 
the soft tissues makes it very difficult to obtain a clear con-
trast in an X-ray image. Therefore, X-rays are unsuitable for 
soft tissue imaging in HNC, including lymph nodes, where 
CT and MR are the most important [19]. However, in terms 
of bone system diagnostics, X-ray is the “gold standard” and 
the most frequently performed examination used to assess 
metastatic lesions to bones or their direct infiltration by a 
tumor developing nearby [25]. Lesions like “pepper pot skull” 
or “raindrop skull” (lesions resembling an image of a raindrop 
splashing against the ground) — symptoms characteristic 
of multiple myeloma lesions in the skull bones, also can be 
observe during imaging the head region using X-ray [26, 27].
X-ray except the bone structures allows for good vi-
sibility of pulmonary tissue [19]. It is often used to detect 
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possible HNC metastatic lesions in the lungs or synchronous 
lung cancer. This examination carried out in two projections 
(anterior-posterior and lateral) is a minimum in terms of the 
assessment of the M parameter (according to TNM) in the 
chest area [20]. However, in comparison to the “gold stan-
dard” of CT in chest region diagnostics, X-ray examination 
is burdened with a significant percentage of false negative 
results [28].
X-ray images are also used during the initial simulation, 
which is the stage of radiotherapy planning. X-ray allows 
to localize neoplastic lesions, as well as to predefine the 
geometry of the radiation beam, including the shape and 
position of therapeutic fields with simple two-dimensional 
RT planning. However, increasingly X-ray is replaced by a 
simulation with the CT device [29]. 
X-ray images are also used to verify the position of 
the patient before starting the radiotherapy — these are 
the so-called portal images taken in the linear accelerator 
room with a megavolt photon beam. In next step they are 
compared with 2D images documenting the position of 
the patient, obtained during the initial simulation in the 
simulator’s room [30]. 
A more modern method of verifying a patient posi-
tioning based on X-ray images is EPID (electronic portal 
imaging device) — a system for portal imaging that re-
cords X-ray images in an electronic form. EPID is a more 
accurate method, which also allows for in vivo measure-
ments [31, 32]. X-ray position verification is used not 
only in the case of photon beam radiotherapy, but also 
in proton therapy [33]. Currently, more and more tech-
nologically advanced systems are being constructed to 
verify the position of a patient — not only before the 
start of treatment, but also during each RT fraction. One 
of such systems is BrainLab’s ExacTrac®, consisting of 
an infrared optical positioning system (ExacTrac) — for 
pre-setting and precise motion control of the therapeutic 
couch and a kV-based X-ray imaging system (X-ray 6D) to 
verify a patient’s position. The X-ray 6D system consists 
of two X-ray radiation sources placed in the floor, which 
emit slanting X-ray beams intersecting in the isocenter, 
received by compatible detectors mounted on the ceiling. 
The 6D fusion software generates sets of digital radio-
grams based on three axes (x, y, z) and three different 
angles (obtained by moving the couch). The image sets 
are automatically, in real time, matched with the CT per-
formed for RT planning. The obtained  shifts values are 
transferred on-line to the patient’s positioning system, 
which automatically introduces changes to the patient’s 
position. The ExacTrac® system is used in patient position-
ing during highly specialized radiotherapy procedures 
such as IMRT (intensity modulated radiotherapy) or SRT/
SBRT (stereotactic radiotherapy/stereotactic body radio-
therapy), performed in the head and neck area [34–36].
Computed tomography
Computed tomography (CT) is a recognized and widely 
used method allowing for spatial imaging of head and neck 
region tissues. In CT devices, the X-ray tube emitting X-rays 
moves around the examined object, and the changes in the 
intensity of radiation after passing through the patient’s 
body are recorded with the use of detectors located on the 
periphery of the device. Afterwards, the received measu-
rement values are processed electronically and an image 
reconstruction is obtained [13]. The features of the primary 
neoplasm (location, dimensions, infiltration on adjacent 
structures, presence of necrosis) of other head and neck 
organs for the presence or exclusion of a second, indepen-
dent tumor and the condition of regional lymph nodes are 
Figure 1. Use of X-ray images to verify a patient’s positioning before 
starting radiation therapy (a, b, c, d) and in two-dimensional planning 
(2D) of radiation therapy (e, f). Photographs a and c are reference 
images, while photographs b and d are verification images. In order 
to determine the mutual position of the fields in both pictures, 
the same anatomical structures were marked. The next step is to 
superimpose the images on each other and read the shifts along the 
x, y, z axes
a)
c)
e)
b)
d)
f )
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routinely assessed in CT [14]. The CT examination is charac-
terized by lower accuracy of soft tissue imaging, where MR 
has a significant advantage, however, bone structures and 
cartilage tissue, e.g. thyroid cartilage, are very well visible 
[8]. Therefore, it is possible to detect the infiltration of these 
structures by the cancer. Determination of bone or cartilage 
infiltration significantly influences therapeutic decisions. 
This method is also a useful tool in determining the stage of 
N parameter (according to TNM). In the meta-analysis carried 
out by Sung et al. [37] higher sensitivity of CT (84%) vs MR 
(80%) in the detection of enlarged lymph nodes, with lower 
specificity of CT examination (72% vs 81%) was proven. 
In the group of patients with HNC, the lungs are the most 
frequent location of metastases, as well as the second inde-
pendent tumor [2, 11]. The CT examination is an effective 
method of imaging of pulmonary tissue pathology, hence 
its well-established place in the protocols for determining 
the clinical advancement stage in patients with HNC [2, 8]. 
The second most frequent location of HNC metastases are 
bones [11]. Among the imaging techniques in this case the 
CT is of great importance. This examination has a significant 
advantage over X-rays, especially in diagnostics of lesions 
in flat bones and complex bones (pelvic bones, scapula, 
vertebral column, ribs), which are usually not sufficiently 
clear on X-ray images. The CT makes it possible to assess the 
depth of cancer infiltration in individual parts of the bone: 
the cortical layer and the cancellous bone. 3D reconstruction 
of CT images helps to diagnose superficial bone lesions. The 
CT shows the damage of the bone structure by cancer, bone 
fractures, mineralization of the bone matrix and periosteal 
lesions better than the MR [25].
Despite its limitations, CT is often used especially in 
diagnostics before therapy [9]. However, the examination 
requires the administration of an intravenous iodine con-
trast agent, which visualizes vascular structures and thus 
provides more information. HNCs are well vascularized, 
so the contrast allows for better imaging (contrasting) [8, 
38]. Analysis comparing CT scan with intravenous contrast 
and PET/CT scan for metastatic lymph node detection in 
preoperative management in patients with HNC did not 
show statistically significant differences in sensitivity of both 
examinations, however, it indicated at a higher specificity 
of CT with contrast [39]. Taghipour et al. [40] demonstrated 
that CT with contrast and PET/CT have a similar precision 
in the assessment of the primary neoplasm site in the local 
and regional assessment of patients with squamous cell 
carcinoma of the oropharynx after radical treatment. 
The use of iodine-contrasting agents may result in the 
occurrence of certain undesirable side effects. One of them 
is renal damage (CIN — contrast-induced nephropathy), 
with decrease in glomerular filtration rate as the main symp-
tom. Chronic renal disease and diabetic nephropathy are 
particular risk factors for CIN. Other factors increasing the 
probability of post-contrast nephropathy are dehydration, 
severe heart failure, diuretics and nonsteroidal anti-inflam-
matory drugs. The adverse effects on the kidneys depend 
on the osmolarity, dose and route of administration of the 
contrast agent and on the time elapsed since the previous 
examination with this type of substances. The biggest nega-
tive impact on kidneys is observed in the case of contrasting 
medium of high osmolarity (1400–2100 mOsm/kg), which 
are rarely used now. Lower risk (5–10 times) is associated 
with the administration of low osmolarity (500–800 mOsm/
kg) and isosmotic (290 mOsm/kg) agents. Other side effects 
associated with the use of iodine contrast substances are 
allergic reactions. Patients with a history of moderate to 
severe allergic reaction to contrast media, bronchial asthma 
and allergies requiring treatment are particularly at risk. The 
use of a highly osmotic agent also increases the risk of this 
type of reaction. The administration of iodine contrast media 
is contraindicated in patients with evident hyperthyroidism 
(e.g. untreated Graves-Basedow disease, toxic multinodular 
goiter) due to the high risk of thyrotoxicosis [41].
A certain burden on the patient with CT is the dose of 
ionizing radiation that he or she receives during the en-
tire examination. According to the FDA (Food and Drug 
Administration), the individual risk associated with a CT 
scan, necessary in a given clinical situation, is relatively low 
compared to the benefits brought by adequate diagnostics 
[42]. Another CT deficiency is the occurrence of artifacts, 
the source of which are dental fillings and implants, ob-
scuring the structures of the oral cavity and partially of the 
oropharynx [2]. New algorithms are being developed in 
tomographs’ software in order to eliminate the impact of 
artifacts on the image. It also helps to reduce the effect of 
the mobility of anatomical structures during breathing and 
swallowing, especially in patients who have problems with 
lying motionless for a long time [8]. 
CT scan after intravenous contrast agent administra-
tion is the basis for planning radiotherapy, one of the main 
methods of HNC treatment [2, 14]. The obtained CT images 
are sent to computer software used for treatment planning, 
where the radiotherapist determines, directly on CT scans, 
the volume of the tumor, nodal areas, tumor or nodal bed, 
metastatic focus and healthy organs [43]. CT imaging is 
also used in the process of verifying the position of the 
patient before radiotherapy starting, especially in the case 
of radiotherapy techniques requiring precise location of the 
irradiated area, i.e. SBRT or IMRT. Among the tools used for 
this purpose, these are the most common in clinical practice: 
CT-on-rails (a tomograph moving on rails in a therapeutic 
device room), kV CBCT (cone beam computed tomography), 
where the radiation beam originates in a X-ray tube attached 
to the arm of the radiotherapy device) and MV CBTC (CBCT 
using a megavolt beam generated by a linear accelerator) 
[34, 44, 45].
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HNC treatment should have a chest CT because of the incre-
ased risk of lung cancer, especially in smokers [14, 46, 47]. 
RECIST criteria (response evaluation criteria in solid tu-
mors), are used to assess the response to chemotherapy and 
ir-RECIST (immune-related RECIST) for immunotherapy. The-
se criteria are based on a comparison of the size and number 
of neoplastic lesions measured in the initial and control — 
after treatment — CT [48]. A study by Kim et al. [49] which 
Figure 2. Use of computed tomography in radiotherapy planning and verification of the patient’s positioning before starting radiotherapy. 
Radiotherapy planning with IMRT (intensity modulated radiotherapy): arrangement of radiation beams (a), distribution of radiation dose in the 
form of isodoses on the transverse cross-section (b) and sagittal cross-section (c). VMAT (volumetric modulated arc therapy) radiotherapy planning: 
distribution of the dose over the transverse (d), sagittal (e) and frontal (f) cross-sections. Verification of patient positioning by superimposing the 
location CT images (pink) and kV CBCT (cone beam computed tomography) made before irradiation (green) on the transverse (g), sagittal (h) and 
frontal (i) cross-section. The computer system reads shifts along the x, y, z axes and then corrects the position of the patient
a) c)
e)
g) i)
b)
d) f )
h)
Performing a CT scan was also one of the recommen-
dations during the follow-up of HNC patients. According 
to the algorithm of NCCN (National Comprehensive Cancer 
Network), as well as the Polish and European guidelines — 
the CT examination of the head and neck region should 
be performed not earlier than 6 months after the end of 
treatment and also not more often than every 6 months. 
NCCN’s recommendations also suggest that patients after 
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compares methods of diagnostics of local/regional HNC 
recurrences, shows that the sensitivity and specificity of CT 
in this aspect is: 89.9% vs 85.7%, respectively.
Magnetic resonance 
Magnetic resonance (MR) is an imaging method of cho-
ice for the head and neck region diagnostics [2]. It does not 
use ionizing radiation, so in this regard it is a safer method 
than CT. The basis of the MR method is the phenomenon 
of nuclear magnetic resonance, consisting in excitation of 
nuclei of hydrogen atoms in tissues located in an exter-
nal magnetic field, through rapid changes in this field. The 
electromagnetic radiation caused by the system’s return to 
equilibrium is recorded and processed by computer systems. 
The diagnostic accuracy of the MR is influenced, among 
others, by the magnitude of the magnetic field strength 
expressed in tesla (T). The higher the T number, the bet-
ter the contrast between the different structures, which 
is particularly important in the assessment of tissues and 
organs in the head and neck region, where a large number 
of small adjacent structures such as nerves, vessels and 
lymph nodes are present. Currently, 1.5T and 3T devices 
are standard equipment of radiology departments, while 
7T systems are at the experimental testing phase [50, 51]. 
The MR examination includes various options — sequences 
that can be performed in a single session on this diagnostic 
equipment. Each subsequent sequence prolongs the exa-
mination time by 2–10 minutes, during which the patient 
must remain motionless in one position, which may be 
a problem, for example, for patients with bone and joint 
pain [2, 8]. However, individual MR sequences offer new 
possibilities to differentiate between benign and malignant 
lesions. The standard sequences in the MR examination are: 
T1-weighted scan — shows individual anatomical structures 
in excellent resolution, T2-weighted scan — shows edema 
and related pathologies. STIR (short TI inversion recovery), 
on the other hand, eliminates disturbances originating from 
adipose tissue [8]. Newer sequences, now widely studied, 
are DWI (diffusion-weighted imaging) and ADC (apparent 
diffusion coefficient). The DWI sequence shows diffusion, 
i.e. movements of water molecules in the extracellular spa-
ce, reveals the structure of the tumor and depends on the 
density of cells in a given tissue. Reduction of diffusion gives 
a high DWI signal (hyperintense foci, “lighter” spots), which 
is used to characterize and evaluate the extent of cancer 
infiltration. Changes that resemble edema, fibrosis, inflam-
mation decrease the DWI signal (hypointense, “darker” foci). 
However, sometimes there are deviations from this rule: 
tumor necrosis decreases the DWI signal, which can make 
it difficult to estimate the size of the tumor, while non-ma-
lignant ulceration increases the DWI signal suggesting its 
neoplastic origin. Also some normal tissues, i.e. lymphatic 
tissue and salivary glands are characterized by an increased 
DWI signal, so this sequence becomes less useful in the dia-
gnosis of metastases to lymph nodes. The ADC sequence is 
used to diagnose and describe primary lesions, but above 
all, to monitor responses to non-operative treatment, i.e. 
radio- or chemotherapy (CT). It allows to distinguish local 
recurrences from inflammatory lesions or fibrosis after RT, 
which gives an advantage over PET scans, which do not 
always allow for such differentiation [2]. Currently, the pre-
dictive value of the ADC sequence is subject to verification 
in clinical trials. Preliminary studies show that the increased 
ADC in the tumor before treatment — associated with the 
presence of necrosis, low cell density and a high compo-
nent of stroma in tissue — correlates with a higher cancer 
resistance to radiochemotherapy (RCT) [52]. 
The cross-sections obtained from MR are characterized 
by very good imaging of soft tissues due to high contrast 
between individual structures [2, 8, 53]. MR can be used to 
a) b) c)
Figure 3. Use of computed tomography (CT) to evaluate the results of combined therapy. A male patient with squamous cell carcinoma of the 
tonsil, in clinical stage of T2N3M0. (a) CT of the neck region before treatment — a visible bulky lymph nodes of group III cervical nodes on the right 
(arrow). (b) after induction chemotherapy (3 courses of TPF). (c) a follow-up exam after radical MV IMRT (intensity modulated radiotherapy) up to 
the total dose of 70 Gy in 35 fractions with simultaneous chemotherapy with weekly cisplatin at 40 mg/m2
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accurately visualize the boundaries of the tumor and the 
infiltration of adjacent structures. This study is particularly 
well suited for the diagnosis of perineural infiltration [2, 53]. 
However, MR examination has limitations — it is characteri-
zed by poorer quality of bone structure imaging. Therefore, 
in the case of infiltration of e.g. skull base structures, the CT 
is an examination of choice, which visualizes bones much 
better than MR[54]. The specificity of MR, determined in a 
meta-analysis by Sun et al. in relation to the diagnosis of 
metastatic lymph nodes in HNC, is significantly higher than 
CT (81% vs 72%), with lower sensitivity of MR in this regard 
(80% vs 84%). In diagnostics of HNC distant metastases, MR 
is particularly useful in imaging lesions in the brain. T1- and 
T2-weighted sequences are routinely performed, as well 
as the pathological contrast enhancement evaluation in 
order to determine the structure of the tumor. The FLAIR 
sequence, on the other hand, provides an excellent contrast 
between metastatic lesion and nerve tissue [50, 55]. In ad-
dition, for the diagnosis of hepatic metastases, the T1- and 
T2-weighted sequences, the DWI sequence and the use of 
an intravenous contrast agent provide accurate imaging 
of lesions with varying degrees of vascularity [56]. In the 
diagnosis of liver tumors, MR and CT examinations show 
similar sensitivity, with a slight predominance of MR [55].
Magnetic resonance spectroscopy (MRS) allows for 
the analysis of the concentration of metabolites in tissues 
exposed to electromagnetic radiation. One of the more 
common MRS techniques used in HNC assessment is the 
proton MRS (1H-MRS), which detects increased choline me-
tabolites (Cho) in tumor tissues, reflecting cell proliferation 
and changes in cell membrane. Elevated Cho/creatine (Cr) 
ratio is characteristic for squamous cell HNC. Regions of 
hypoxia and necrosis in tumors are described by the peak 
of lipids and lactates in the spectroscopic analysis [56].
During the MR examination it is possible to use an in-
travenous contrast agent, based mostly on chelated gado-
linium compounds. In some cases tissue-specific contrast 
agents can be used, e.g. in the diagnosis of hepatic me-
tastatic lesions, these will be the agents containing iron 
oxide molecules showing affinity to the reticuloendothelial 
system and hepatocytes [13, 57]. Until recently, these me-
dia, in contrast to those used during CT, were considered 
to be completely safe, also for patients with renal diseases. 
However, studies have shown an increasing incidence of 
nephrotoxicity and nephrogenic systemic fibrosis (NSF) after 
gadoline-based agent administration, and the risk of these 
complications increases with deteriorated renal function 
[58]. Another contraindication for MR scan is the presence 
of metal elements in the patient’s body (cardiac pacemakers, 
cochlear implants, intrauterine contraceptive devices, metal 
shavings in an eyeball, surgical clips, metal surgical stitches), 
which is caused by the use of high intensity magnetic field 
during the examination. Although the latest stimulation de-
vices (cardiostimulators, etc.) are already manufactured from 
alloys that are not contraindications for MR scanning, they 
are nevertheless a source of image-distorting artifacts [59]. 
In addition to its obvious role in the initial imaging dia-
gnostics of patients with HNC, MR is used in the treatment 
planning process — RT — of both primary tumors and 
distant metastases (e.g. CNS). The new generation of devi-
ces dedicated to teleradiotherapy are combinations of MR 
with a linear accelerator or a device containing a source of 
cobalt-60. Such hybrids allow, among others, to obtain a 
high contrast of soft tissues, no exposure to X-rays, or no 
need to implant markers in order to position the patient 
on the therapeutic device [60]. Although RT planning is 
currently still based on the CT scan, new programs and 
algorithms compatible with modern hybrid devices are 
being developed, allowing RT to be planned directly from 
MR scans, which would increase the precision of treatment 
[2, 59]. However, the standard of conduct, among others in 
RT changes in the CNS, is the determination of areas to RT 
based on the fusion of the basic CT scan with a diagnostic 
MR examination or MR performed in a therapeutic position, 
a)
c)
b)
d)
Figure 4. Image of metastatic lymph nodes (arrows) in sequence 
(a) T1- weighted TSE (turbo spin echo), (b) DWI (diffusion-weighted 
imaging) and (c, d) PET/MR. (a, b) A female patient with T2N2cM0 
squamous cell carcinoma of the tonsil with bilateral metastases 
to cervical lymph nodes of group II. (c, d) A female patient with 
T3N2bM0 squamous cell carcinoma of the left buccal mucosa with 
metastatic lymph nodes in group II (c) metastatic bulky lymph nodes 
(d) in group III on the right side (arrow)
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so far (still, few centers have a special “attachment” to the 
MR device serving this purpose) [61]. 
According to the recommendations of NCCN [47], MR 
may be used as a follow-up examination after the end of 
treatment of patients with HNC according to the following 
scheme: first MR imaging after 6 months from the end of 
treatment, another at intervals of 6 months or in case of 
recurrence suspicion. MR in comparison with CT seems to be 
a follow-up examination of choice, mainly due to the greater 
possibility of visualization of small anatomical structures in 
soft tissues and differentiation between the lesions after RT 
and the local recurrence. Only in case of suspicion of bone 
structure infiltration the diagnosis should be additionally 
deepened by CT scan [54]. The sensitivity and specificity of 
MR as a follow-up examination, especially when using the 
DWI sequence, is high — over 90% [62].
However, not all centers have MR equipment at their 
disposal due to high costs of equipment purchase. CT is 
relatively cheaper and thus more widely used in clinical 
practice compared to MR [63].
Angiography
Angiography is an invasive method of blood vessel exa-
mination, which consists in injecting a contrast agent into 
the vessel and registering a series of X-ray images. It allows 
to differentiate tumors of vascular origin from solid tumors 
and to visualize places of bleeding. In the case of tumors 
with properly depicted vascular system, this examination 
can be combined with endovascular obliteration [64]. HNC 
are the main causes of difficult to control hemorrhages 
— spontaneous, as well as complications of oncological 
treatment. Diagnostic angiography with vascular contrast 
is a key examination in such cases. A presence of angiogra-
phic catheter enables embolization of the pathologically 
changed vessel, which effectively prevents life-threatening 
hemorrhages [65]. 
Currently, the role of non-invasive methods, such as 
computed tomographic angiography (angio-CT), is incre-
asing. It is a method of vessel imaging with the use of spiral 
CT after intravenous contrast administration [66]. This me-
thod is used for mapping of blood vessels of the limb and 
their evaluation before the collection of the skin flap for 
transplantation, as part of reconstruction operations of de-
fects resulting from surgical treatment of patients with HNC. 
Appropriate diagnostics of skin graft vascularity prevents 
rejection of the transplant due to local blood circulation 
insufficiency and allows to maintain effective vascularity of 
the limb from which the graft was taken [67, 68].
Similarly, magnetic resonance angiography (MRA) is 
also used. The quality of vascular imaging in both methods 
is similar. It is possible to perform both of these examina-
tions using the whole-body technique, which allows for the 
assessment of vascularity at the place where the skin graft 
is collected and at the target transplant site [69].
Positron emission tomography (PET)
PET scan is a method of molecular imaging of tissues, 
increasingly used in the diagnosis of cancer. The basis of this 
technique is the phenomenon of annihilation of positron-
-electron pair, as a result of which high-energy photons 
are created. The positrons are derived from the radioactive 
decay of a radiopharmaceutical component administered 
a) c)b)
Figure 5. An artifact in imaging examinations. An artifact (yellow arrows) from amalgam tooth fillings in the CT (a), MR (b) and PET/MR (c) images, 
making it difficult to diagnose lower gingiva lesions on the left side (red arrows)
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to the patient. The source of electrons are tissues and body 
fluids of the patient. The radiopharmaceutical component 
accumulates in characteristic tissues, and the spatial distri-
bution of photon emission is the initial image of the study. 
90–95% of PET tests are performed with deoxyglucose ra-
diolabeled with fluorine 18 (18F-FDG). This compound is 
transported to the cell in the same way as glucose and, just 
as glucose, is subjected to glycolysis processes until the 
phosphorylation reaction, the products of which are then 
deposited in the cell [2, 70]. The phenomenon of increased 
glucose uptake and metabolism compared to normal tissues 
is characteristic for most types of cancer [70]. It also occurs 
in: inflammation, edema, infection, pre-cancerous lesions, 
healing postoperative lesions, directly after the effort in 
skeletal muscles and physiologically in the brain tissue. 
The above mentioned changes in glucose uptake may lead 
to false positive diagnoses, on the other hand, increased 
glucose metabolism in muscles or brain tissue may form 
a background hindering the proper diagnosis of the tumor 
[2, 8]. Anderson et al. [70] demonstrated the possibility of 
distinguishing 18F-FDG uptake caused by inflammation from 
the one caused by cancer. These cases differ in the uptake 
kinetics of 18F-FDG: during the examination, in 60–120 minu-
tes after administering the radiopharmaceutical substance, 
a decrease was observed in 18F-FDG accumulation in the 
inflammatory site, while 18F-FDG metabolism was still incre-
asing in the tumor tissue. On the other hand, e.g. necrosis 
in a neoplastic tumor, high blood glucose and insulin levels 
affect false negative results [2]. 
Although 18F-FDG is a commonly used radiopharma-
ceutical substance in PET studies, PET imaging also uses 
alternative radiotracers — not only in experimental studies, 
but more and more often in clinical practice. One of them is 
18F-fluoromisonidazole (FMISO), which in the case of HNC 
allows for illustrate the foci of hypoxia and perfusion in 
tissues [71]. These factors have a predictive value in the 
treatment of HNC patients — hypoxia in the tumor area 
has a negative impact on RT treatment results [72]. FMISO 
belongs to the group of nitroimidazoles — chemical com-
pounds which were developed as early as in the 1970s as 
markers of cell hypoxia and were used as “radiosensitizers” 
— substances increasing the sensitivity of cells for ionizing 
radiation [73]. Nitroimidazoles in hypoxic cells are reduced 
to form of a reactive intermediate compound. Under normal 
conditions these molecules are re-oxidized to the parent 
compound and diffuse from the cell. However, hypoxia 
causes further reduction and the compound is irreversibly 
trapped in the cell. These reactions occur at a rate that is 
inversely proportional to the oxygen pressure in the cell. 
Since the reduction of nitroimidazoles requires the presence 
of active tissue reductases, these compounds accumulate 
in living, oxygenated cells, but are not found in cells under-
going apoptosis or necrosis [74].
Promising results of clinical studies on HNC hypoxia 
imaging are also associated with another nitroimidazole — 
18F-fluoroazomycinarabinozide (18F-FAZA), but its clinical 
usefulness must be confirmed in further studies [75]. Other 
radiotracers are in the experimental stage, i.e.: 18F-FETNIM 
(18F-fluoroerythronitroimidazole), 18F-EF5 (18F-2-(2-Nitro-1-
H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide) 
and Cu-ATSM (Cu-diacetl-bis (4N-methylthiosemicarbazone)) 
— hypoxia markers, 18F-FET (18F-fluoroethyl-L-tyrosine) — se-
lectively accumulated in cells of squamous cell HNC and allo-
wing for differentiation of inflammatory reaction from cancer 
and 11C-choline (CHOL) — accumulated in malignant tumors 
similarly to 18F-FDG, but to a lesser extent in muscles, which 
eliminates background artifacts hindering diagnostics [74, 
76–78]. The problem with the use of alternative radiophar-
maceuticals is the short half-life period of these compounds. 
This results in the given centre’s need to have a cyclotron for 
the production of such radiotracers. It entails significant costs, 
which means that only few centers can perform PET scans 
with substances other than 18F-FDG [79].
Positron emission tomography/Computed 
tomography (PET/CT)
The enrichment of functional PET imaging with CT fu-
sion increases the precision of the method through better 
anatomical mapping, allowing for more accurate localization 
and evaluation of the morphology of metabolic variations 
[80]. The CT scan performed within PET/CT is a low-dose 
X-ray examination without intravenous contrast agent. It 
is not a fully diagnostic examination. Its aim is to facilitate 
anatomical localization of foci of increased glucose uptake 
[81]. Therefore, PET/CT is rarely used to evaluate the tumor 
because of the weak tissue contrast obtained in CT scans 
without intravenous contrast agent. Insufficient detection of 
small tumors, not exceeding 5 mm, is also an imperfection 
of the examination. Compared to other imaging methods, it 
is more accurate in detecting metastatic lymph nodes. The 
sensitivity and specificity of PET/CT in the determination of 
the N parameter (according to TNM) is 80% and 86%, respecti-
vely. It is also possible to visualize eventual distant metastases 
or a synchronous tumor during a single examination, due 
to the fact that the entire patient’s body is included in the 
PET/CT scan [2]. This method is also applicable for detecting 
a primary tumor in the case of lymph node metastases from 
an unknown primary [2, 8]. Such cases constitute 2–7% of all 
HNCs. In 25–54% of them a primary tumor is identified by PET/
CT scan. However, the most important role of PET/CT in the 
imaging diagnostics of the head and neck region is to monitor 
the effects of treatment after radical RCT. In order to prevent 
false positives, PET/CT should be carried out no earlier than 3 
months after the end of treatment [2, 82]. The sensitivity and 
specificity of PET/CT in the determination of possible residual 
lesion/recurrence is 94% and 82%, respectively [2]. A negative 
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PET/CT scan 12 weeks after the end of RCT is currently the 
best positive prognostic factor [83]. The PET/CT examination 
is characterized by a high negative prediction value [82]. It 
helps to prevent unnecessary surgeries after an earlier RCT, 
which increase mortality rate among this group of patients. 
For economic reasons, this examination is also a cost-effective 
tool to control the effects of treatment [2, 83].
Modern RT techniques allow to administer a sufficiently 
high dose of ionizing radiation to the tumor area with maxi-
mum healthy tissue sparing. Therefore, irradiation volumes 
must be precisely defined and one of useful examinations 
in this respect is PET/CT. The detection of pathological foci 
of increased 18F-FDG uptake in lymph nodes of normal size 
allows to covered them with an appropriately high dose of 
ionizing radiation — thus increasing the probability of radical 
treatment. On the other hand, PET/CT may reveal necrotic le-
sions in the tumor, which will result in a smaller target volume 
and decrease volume of healthy tissue in the irradiated area. 
The main problem with the use of PET/CT in the definition 
of RT volumes is the determination of the cut-off point of 
the 18F-FDG uptake (SUV — standardized uptake value). This 
may lead to overestimation or underestimation of the volu-
me of neoplastic lesions [84]. Some researchers contoured 
the areas on the basis of 50% of the maximum intensity of 
18F-FDG uptake by the tumor [85]. Others considered 18F-FDG 
uptake by liver tissue uptake as the limit value [86]. Wang et 
al. [87] investigated the SUV value above 2.5 as the basis for 
contouring the target volumes. Despite the lack of consensus 
on this issue, the vast majority of researchers demonstrated 
a positive effect of the PET/CT on the precision of the deter-
mination of the irradiation volume [84].
Positron emission tomography/Magnetic 
resonance (PET/MR)
A hybrid of PET and MR is a modern combination of 
high quality anatomical MR and functional and metabolic 
a)
d)
c)
f )
b)
e)
Figure 6. Use of PET/MR in diagnostics of the head and neck region tumors. (a, b) A female patient with diagnosed keratinized squamous cell 
carcinoma of the right submandibular salivary gland (arrow) at T3N0M0 clinical stage. (c, d) A female patient with squamous cell carcinoma of the 
left buccal mucosa (c) at T3N2bM0 clinical stage, (d) a metastatic cervical lymph node at the borderline of left III and IV groups. (e, f) Patient with 
diagnosis of squamous cell carcinoma the floor of the mouth at T1N2cM0 clinical stage (e), a metastatic lymph node of left group II of cervical 
lymph nodes (f)
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imaging obtained from PET using most often 18F-FDG [88]. 
There are only several studies that have evaluated the clini-
cal benefit of such a combination in the diagnosis of patients 
with HNC, so far. PET/MR seems to have an advantage over 
PET/CT, among others, due to the possibility of obtaining 
simultaneously high contrast in soft tissues and fewer arti-
facts derived from implants and dental fillings [87, 88]. The 
use of low-dose CT in PET/CT speaks in favor of PET/MR 
imaging [89]. Another advantage of PET/MR hybrid is the 
possibility of using individual sequences of fully diagnostic 
MR, such as DWI sequence, T1- and T2- weighted sequence 
[90, 91]. The sensitivity and specificity of the PET/MR in HNC 
diagnostics has not yet been determined, but on the basis of 
preliminary studies it seems to be particularly useful in the 
imaging of metastatic lymph nodes and in case of suspicion 
of recurrence after radical treatment. The promising results 
also concern the use of PET/MR hybrids in the diagnosis 
of HNC distant metastases into the liver and brain and as 
a basis for planning areas for radiotherapy [88–90].
Scintigraphy
As mentioned earlier, the skeletal system is the second 
most frequent location of HNC metastases [11]. Scintigra-
phic scan is a standard procedure in the diagnosis of bone 
metastases. It is one of the longest used techniques of nuc-
lear medicine, whose principle of operation is similar to PET 
scans. A patient receives an intravenous radiotracer and 
then the whole body is scanned using a gamma camera. 
Unlike PET, the image obtained during scintigraphy is a pro-
jection of the bone system in one plane [91, 92]. A scan 
with radiotracers consisting of diphosphates radiolabeled 
with technetium-99 (99Tc) has a high sensitivity (> 90%) 
to detect changes in bones. However, studies [91, 93, 94] 
have shown that in the diagnosis of bone metastases PET/
CT is characterized by higher precision in the localization 
of bone lesions, as well as higher sensitivity and specificity 
than scintigraphy, especially when the radiotracer in PET/CT 
is [18F]-NaF (sodium fluoride radiolabeled with 18-fluoride).
Scintigraphy is also used in the assessment of salivary 
gland function in connection with planned radiotherapy 
treatment in HNC. RT in the head and neck region often 
causes xerostomia as a result of salivary gland damage and 
secretive function disorders. Therefore an attempt to pro-
tect salivary glands as risk organs during the RT planning. 
Scintigraphy is performed after administration of 99Tc, and 
the image of the salivary glands suggests which gland or 
area of the gland is the most secretively active. This helps 
to determine which areas should be particularly protected 
during RT planning [95, 96].
Summary
Anatomical and metabolic imaging methods differ in 
sensitivity, specificity and diagnostic accuracy. Information 
obtained thanks to them supports making the right therapeu-
tic decision, precise implementation of medical procedures 
(e.g. diagnostics, radiotherapy) and monitoring of treatment 
results. Each of these methods has its strengths and weaknes-
ses in HNC imaging, so the choice of therapy should not be 
made on the basis of a single imaging examination.
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